Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorukafusp alfa - Apeiron Biologics

Drug Profile

Lorukafusp alfa - Apeiron Biologics

Alternative Names: Anti-ganglioside-GD2-antibody-interleukin-2-fusion-protein; APN 301; ch14.18-IL2; EMD 273063; hu14.18-IL2

Latest Information Update: 28 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexigen Pharmaceuticals
  • Developer Apeiron Biologics; Merck KGaA; National Cancer Institute (USA); University of Wisconsin-Madison
  • Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Neuroblastoma

Most Recent Events

  • 19 Jan 2022 University of Wisconsin in collaboration with National Cancer Institute, Bristol-Myers Squibb, Apeiron Biologics and Provenance Biopharmaceuticals suspended the I/II trial in malignant melanoma (Inoperable/Unresectable, Combination therapy, Late-stage disease) in USA, due to administrative decision (Intratumoural) (NCT03958383)
  • 29 Jul 2021 University of Wisconsin in collaboration with National Cancer Institute, Bristol-Myers Squibb, Apeiron Biologics and Provenance Biopharmaceuticals reinitiates a phase I/II trial in malignant melanoma (Inoperable/Unresectable, Combination therapy, Late-stage disease) in USA (Intratumoural)(NCT03958383)
  • 28 Apr 2021 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top